Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Introgen Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (53)	5/11/2004 4:02:01 PM
From: zeta1961	Read Replies (1) \| Respond to of 802

Thanks Ian for posting these...I've never seen a startup with over 20 clinical trials going, multiple preclinicals with that kind of a burn rate...NCI and other grants footing the bill for most of their work... Of course, the Advexin h/n progress, BLA progress/partnering progress(or non-disclosure of) is holding back this stock... Perhaps this CC will shed some light...but doubt it given their history and conference season approaching...INGN is not known to give pps driving events during their CC's.... Should be an interesting one as the analysts are going nutty about their choice to not disclose P3's 'til BLA approval... Zeta